FDA Approves Enspryng for Thyroid Eye Disease, the First At-Home Subcutaneous Treatment for the Condition
The Food and Drug Administration (FDA) on October 16 approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED), Roche announced the same day in Basel. The approval makes Enspryng the first and only at-home subcutaneous treatment option for the condition and the first interleukin-6 receptor (IL-6R) inhibitor approved for the indication; after training from a health care provider, patients or caregivers can administer the injection themselves, every four weeks during the maintenance phase. Thyroid eye disease is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the United States and can lead to facial disfigurement and vision-threatening complications if left untreated. The approval rests on the Phase III SatraGO-1 and SatraGO-2 studies, which enrolled 258 patients in total. In SatraGO-2, 52.9 percent of patients with active disease treated with Enspryng achieved a proptosis response, compared with 23.4 percent on placebo, and diplopia was reduced in 60.7 percent versus 25.8 percent. SatraGO-1 did not meet its pre-specified primary endpoint at week 24. No new safety signals were identified, and the safety profile was consistent with the drug's known profile. Enspryng was first approved in 2020 for neuromyelitis optica spectrum disorder (NMOSD), making TED its second indication; the FDA had granted priority review to the supplemental application. Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the approval provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices. César A. Briceño, a clinical trial investigator and Associate Professor of Ophthalmology at the Scheie Eye Institute of the University of Pennsylvania, said an effective subcutaneous option could provide greater flexibility for patients and physicians while reducing the logistical burden of infusion-based therapies. (Source: Roche and Genentech announcement, October 16, 2026, and FDA approval information)
Source: GSM · USA (original Chinese edition)
Photo: 图：食品药品监管局（FDA）官方照片，公共领域（FDA总部 White Oak 园区入口）
- 2026-10-16FDA Approves Enspryng for Thyroid Eye Disease, the First At-Home Subcutaneous Treatment
- 2026-10-17FDA Approves Enspryng for Thyroid Eye Disease, the First At-Home Subcutaneous Treatment for the ConditionThis story
